Non-Current Assets
Long-term marketable securities
Neurocrine Biosciences Long-term marketable securities increased by 25.2% to $1.33B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 63.3%, from $815.30M to $1.33B. Over 5 years (FY 2020 to FY 2025), Long-term marketable securities shows an upward trend with a 36.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates a long-term capital preservation strategy, while a decrease suggests the liquidation of long-term investments to fund operations or debt repayment.
Detailed definition
This represents long-term investments in debt securities that the company intends to hold for more than one year. These...
Peer comparison
Used by mature companies with strong cash flows to manage long-term liquidity and investment returns.
Metric ID:
non_current_assets_available_for_sale_securities_debt_se_908f76Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $337.80M | $513.70M | $560.70M | $541.00M | $405.20M | $362.60M | $299.40M | $244.60M | $342.60M | $454.70M | $687.50M | $700.40M | $637.80M | $643.90M | $739.50M | $815.30M | $873.80M | $998.50M | $1.06B | $1.33B |
| QoQ Change | — | +52.1% | +9.1% | -3.5% | -25.1% | -10.5% | -17.4% | -18.3% | +40.1% | +32.7% | +51.2% | +1.9% | -8.9% | +1.0% | +14.8% | +10.3% | +7.2% | +14.3% | +6.5% | +25.2% |
| YoY Change | — | — | — | — | +20.0% | -29.4% | -46.6% | -54.8% | -15.4% | +25.4% | +129.6% | +186.3% | +86.2% | +41.6% | +7.6% | +16.4% | +37.0% | +55.1% | +43.7% | +63.3% |
Range$244.60M – $1.33B
CAGR+33.5%
Avg YoY Growth+35.4%
Median YoY Growth+31.2%
Current Streak7 quarters growth
Long-term marketable securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's long-term marketable securities?
- Neurocrine Biosciences (NBIX) reported long-term marketable securities of $1.33B in Q1 2026.
- How has Neurocrine Biosciences's long-term marketable securities changed year-over-year?
- Neurocrine Biosciences's long-term marketable securities increased by 63.3% year-over-year, from $815.30M to $1.33B.
- What is the long-term trend for Neurocrine Biosciences's long-term marketable securities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's long-term marketable securities has grown at a 36.2% compound annual growth rate (CAGR), from $227.10M to $1.06B.
- What does long-term marketable securities mean?
- Long-term investments in debt securities held for interest income.